drugset / Trial / NCT00839800

Study to Investigate the Efficacy of Symbicort® SMART.

NCT00839800

Phase 3 Completed 2091 enrolled AstraZeneca
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary objective of this study is to compare the efficacy of Symbicort SMART (Symbicort Turbuhaler 160/4.5μg, one inhalation twice daily plus as needed) with Symbicort Turbuhaler 160/4.5μg, one inhalation twice daily plus terbutaline Turbuhaler 0.4 mg as needed, as asthma therapy

Timeline

Start
2009-02
Primary completion
2011-02
Completion
2011-02

Drugs

EvaluationDrugModalityDoseRoute
Comparator Terbutaline Small molecule 0.4 mg
Subject budesonide/formoterol Unknown Inhaled

Indications